Source: CNBC
“Pfizer on Monday said it will seek regulatory approval for a Lyme disease vaccine candidate despite the shot failing a late-stage trial. Pfizer said the vaccine missed the trial’s statistical goal because not enough people in the study contracted Lyme disease to be confident in the results. Still, the company said the shot reduced the rate of infection by more than 70% in people who received the vaccine versus placebo, efficacy the company thinks is strong enough to take to regulators. … A vaccine for Lyme disease isn’t expected to become a best-seller for Pfizer …. But Pfizer had billed the Lyme vaccine results as one of its major catalysts this year, and it represented a chance to introduce the only human vaccine for Lyme disease.” (03/23/26)
https://www.cnbc.com/2026/03/23/pfizer-lyme-disease-vaccine-trial-fda-approval.html